| XLS |
EUR million |
Jan.–Sep. |
Jan.–Sep. |
Profit after tax |
596.0 |
318.2 |
Depreciation/amortization and impairment losses (non-current assets) |
776.5 |
676.8 |
Changes in inventories |
–72.1 |
21.0 |
Changes in trade accounts receivable |
–161.7 |
–126.5 |
Changes in trade accounts payable |
–24.6 |
16.4 |
Changes in provisions |
85.2 |
112.1 |
Changes in other assets and liabilities |
113.6 |
–3.2 |
Neutralization of gain/loss on disposals of assets |
–3.2 |
–5.4 |
Other non-cash income and expenses |
–6.7 |
1.2 |
Net cash flows from operating activities |
1,302.9 |
1,010.5 |
|
|
|
Purchase of intangible assets |
–47.6 |
–70.7 |
Purchase of property, plant and equipment |
–254.2 |
–290.6 |
Acquisitions and investments of non-current financial assets |
–4,856.8 |
–32.8 |
Disposal of non-current assets |
21.7 |
25.8 |
Purchase/sale of marketable securities |
2.1 |
– |
Changes in financial assets covering pensions |
–6.7 |
– |
Changes in other financial investments |
1,397.9 |
–1,068.1 |
Net cash flows from investing activities |
–3,743.4 |
–1,436.4 |
|
|
|
Dividend payments |
–73.1 |
–104.7 |
Profit transfers to E. Merck KG and changes in reserves |
–163.8 |
–54.1 |
Changes in liabilities to related parties |
–9.8 |
–133.1 |
Bonds issued |
3,181.7 |
746.0 |
Changes in current and non-current financial liabilities |
356.0 |
–30.3 |
Net cash flows from financing activities |
3,291.0 |
423.9 |
|
|
|
Changes in cash and cash equivalents |
850.5 |
–2.0 |
Changes in cash and cash equivalents due to currency translation |
–4.3 |
–3.5 |
Cash and cash equivalents as of January 1 |
541.4 |
692.7 |
Cash and cash equivalents as of September 30 |
1,387.6 |
687.1 |
back
